rs375774648
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_000256.3(MYBPC3):āc.836G>Cā(p.Gly279Ala) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000021 in 1,574,236 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_000256.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.836G>C | p.Gly279Ala | missense_variant | 8/35 | ENST00000545968.6 | NP_000247.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.836G>C | p.Gly279Ala | missense_variant | 8/35 | 5 | NM_000256.3 | ENSP00000442795.1 | ||
MYBPC3 | ENST00000399249.6 | c.836G>C | p.Gly279Ala | missense_variant | 8/34 | 5 | ENSP00000382193.2 | |||
MYBPC3 | ENST00000544791.1 | n.836G>C | non_coding_transcript_exon_variant | 8/27 | 5 | ENSP00000444259.1 |
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152106Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000214 AC: 4AN: 186786Hom.: 0 AF XY: 0.0000399 AC XY: 4AN XY: 100330
GnomAD4 exome AF: 0.0000183 AC: 26AN: 1422130Hom.: 0 Cov.: 33 AF XY: 0.0000227 AC XY: 16AN XY: 703710
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152106Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74284
ClinVar
Submissions by phenotype
not provided Uncertain:4
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 29, 2024 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 03, 2019 | This variant has been seen in one patient with HCM (Richard 2003). It's also been reported in an individual who had this and 2 additional MYBPC3 variants in cis (p.Glu441Lys, p.Gln76Ter) and also a variant in MYH7 (p.Ile1927Phe) (Millat 2010). The variant has also been reported in two affected siblings compound heterozygous for this variant and the MYBPC3 Glu258Lys variant, each from one possibly mildly affected parent (Lopes 2014). The variant is in gnomAD at 0.005% (5 alleles) and classified in ClinVar with 2 stars as VUS by CHEO, Stanford, and CSER. In summary, this variant is of uncertain significance but we would lean towards a more likely benign impact. - |
Hypertrophic cardiomyopathy Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jul 20, 2024 | This missense variant replaces glycine with alanine at codon 279 of the MYBPC3 protein. Computational prediction tools indicate that this variant has a neutral impact on protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 20624503, 31513939, 33495597; Lopes 2020). One of these individuals also carried a pathogenic truncation variant in the same gene (PMID: 20624503). This variant has also been reported in one individual affected with dilated cardiomyopathy (PMID: 30871747), and in one individual affected with sudden cardiac death (PMID: 31376648). Additionally, it has been reported in one individual affected with left ventricular outflow tract obstruction who also carried another pathogenic variant in the same gene (PMID: 25127965). This variant has been identified in 7/218120 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Human Genetics, University of Leuven | Oct 31, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 18, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 279 of the MYBPC3 protein (p.Gly279Ala). This variant is present in population databases (rs375774648, gnomAD 0.005%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy or dilated cardiomyopathy (PMID: 30731207, 30871747, 31513939). ClinVar contains an entry for this variant (Variation ID: 42798). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The alanine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Cardiomyopathy Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Nov 21, 2022 | This missense variant replaces glycine with alanine at codon 279 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with dilated cardiomyopathy (PMID: 30871747), at least one individual affected with hypertrophic cardiomyopathy (PMID: 31513939, 33495597; Lopes 2020), and one case of sudden cardiac death (PMID: 31376648). This variant has also been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 20624503) and left ventricular outflow tract obstruction (PMID: 25127965), both of whom carried a known pathogenic variant in the same gene that could explain the observed phenotype. This variant has been identified in 7/218120 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Aug 09, 2021 | - - |
not specified Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Mar 28, 2012 | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. MYBPC3 p.Gly279Ala Based on the data reviewed, we classify this variant as a variant of uncertain significance. This variant has been reported in 2 presumably unrelated individuals with HCM. Richard et al (2003) identified p.Gly279Ala in one individual with HCM who had no other variants in the nine sarcomere genes analyzed. Millat et al. (2010) reported one individual with HCM who had three variants on one MYBPC3 allele (p.Glu441Lys, p.Gln76Ter, p.Gly279Ala) and also had an additional variant in MYH7 (p.Ile1927Phe). Unfortunately age of onset and severity were not reported. There is no segregation data available for p.Gly279Ala. p.Gly279Ala is located in a conserved region of the MYBPC3 gene coding for the linker 1-2 region of the protein. However, p.Gly279Ala results in a conservative amino acid substitution and an Alanine is present at codon 279 in rodent. Variants in nearby codons (p.Arg273His, p.Gly278Glu, p.Arg282Trp) have been reported in association with HCM. This variant was not identified in 100 control individuals by Richard et al. This variant was not listed in dbSNP, 1000 genomes, or the NHLBI exome project database. - |
Primary familial hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 26, 2024 | The p.G279A variant (also known as c.836G>C), located in coding exon 8 of the MYBPC3 gene, results from a G to C substitution at nucleotide position 836. The glycine at codon 279 is replaced by alanine, an amino acid with similar properties. This alteration has been reported in hypertrophic cardiomyopathy (HCM) cohorts; however, clinical details were limited (Richard P et al. Circulation, 2003 May;107:2227-32; Millat G et al. Eur J Med Genet, 2010 Jul;53:261-7; Robyns T et al. Eur J Med Genet, 2020 Mar;63:103754). Additionally, this variant has also been described in dilated cardiomyopathy (DCM), left ventricular outflow tract obstruction, and drug-induced sudden unexplained death cohorts (Lopes LR et al. Int J Cardiol, 2014 Oct;176:1264-7; Cardoso B et al. Rev Port Cardiol, 2017 Mar;36:155-165; Martinez-Matilla M et al. Forensic Sci Int Genet, 2019 09;42:203-212; Sousa A et al. Rev Port Cardiol, 2019 02;38:129-139). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at